PRO MEDICUS LIMITED — Director's Dealing 2025

Dec 22, 2025

Appendix 3Y Change of Director’s Interest Notice

Listing Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Pro Medicus Limited ABN 25 006 194 752

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sam Aaron HUPERT
Date of last notice	22 December 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [408 x 280] intentionally omitted <==

----- Start of picture text -----

Direct or indirect interest Direct
Nature of indirect interest Ordinary fully paid shares in Pro Medicus
(including registered holder) Limited held by ALLHC Pty Ltd as trustee for
Note: Provide details of the circumstances giving rise to the relevant
interest. the Sam Hupert Family Trust.
Date of change 23 December 2025
No. of securities held prior to change 24,189,910 ordinary shares consisting of: -
 24,122,660 ordinary shares held
under Sam Aaron HUPERT
 65,000 ordinary shares held under
Alltogether Superannuation Fund
 2,250 ordinary shares held under
ALLHC Pty Ltd as trustee for the Sam
Hupert Family Trust
Class Ordinary shares
Number acquired 2,250 ordinary shares
----- End of picture text -----

• See chapter 19 for defined terms.

11/3/2002

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

==> picture [409 x 257] intentionally omitted <==

----- Start of picture text -----

Number disposed Nil
Value/Consideration $221.99 per share
Note: If consideration is non-cash, provide details and estimated valuation
No. of securities held after change 24,192,160 ordinary shares consisting of:-
 24,122,660 ordinary shares held
under Sam Aaron HUPERT
 65,000 ordinary shares held under
Alltogether Superannuation Fund
 4,500 ordinary shares held under
ALLHC Pty Ltd as trustee for the Sam
Hupert Family Trust.
Nature of change On market trade
Example: on-market trade, off-market trade, exercise of options, issue of
securities under dividend reinvestment plan, participation in buy-back
----- End of picture text -----

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [409 x 296] intentionally omitted <==

----- Start of picture text -----

Detail of contract N/A
Nature of interest N/A
Name of registered holder N/A
(if issued securities)
Date of change N/A
No. and class of securities to which N/A
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired N/A
Interest disposed N/A
Value/Consideration N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change N/A
----- End of picture text -----

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For and on behalf of Pro Medicus Limited

==> picture [132 x 60] intentionally omitted <==

Danny English Company Secretary 23 December 2025

• See chapter 19 for defined terms.

11/3/2002

Appendix 3Y Page 3